Protection of SARS-CoV-2 trial vaccines in human is a functnion of the viral genomes

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has devastated mankind with complaints that many vaccines developed against the disease could not offer protection and guarantee safety, hence many vaccinated individuals either came down with the infection and died or transmitted the infection. Therefore permanent immunization may become difficult due to interplay between the viral and human genomes. In view of this, literatures were searched on the trial vaccines against SARS-CoV-2.Concentration log10 (copies/ml) of the virus, log10 viral copies, populations of human vaccinated, protection indices of the vaccines, population of Tcells, lethal concentration 1 (LC1) of the virus, doses of the trial vaccines and vaccine regimens of the SARS-CoV-2 obtained from membrane ribonucleic acid (MRNA), replication defective viral vector (RDVV), inactivated pathogen vaccine (IPV), and protein subunit vaccine (PSV),virus like particle (VLP) and deoxyribonucleic acid vaccine (DNAV) were used with an intent to assessing the pathogenicity and virulence of the vaccines. Findings have shown that virion of 3.3 x10 8-9 could kill human over a period of ≥20 days, and 10 9-11virions have killed three in every 100 humans. However, viral load of detection (3.22 x 10 3), positivity threshold (3.3 x 10 3) and index patient value (6.6 x 10 6) respectively have been established. The protection index is between 11-99%. The viral load of coronavirus found in the affected patients was relatively high and could be fatal. However DNAV based vaccine (2 mg) administered twice 4 weeks apart provided the best protection index that lasted for 40 – 60.